Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

collaboration station

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

The pairing of Fannin and MD Anderson makes perfect sense. Researchers at the institution have already identified novel markers that they will target with both Raptamer-based drugs and radiopharmaceutical/radioligand therapies.

“MD Anderson and Fannin bring highly complementary capabilities to the identification of novel cancer targets and Raptamer-based drug discovery,” says Varadhachary in a press release. “Our collaboration will enable us to rapidly develop targeted therapeutics against novel targets, which we hope will offer hope to patients with progressive cancers.”

Early in this meeting of minds, researchers will focus on developing targeted radiopharmaceuticals — the Radiomers for which Varadhachary’s company is named — as well as targeted drug conjugates that utilize Raptamers. Raptamers are an innovative class of targeting vectors that combine a DNA oligonucleotide backbone with added peptide functionality, for oncology indications.

“We are committed to exceptional research that can help us further our understanding of cancer and develop impactful therapeutic options for patients in need,” says Timothy Heffernan, Ph.D., vice president and head of therapeutics discovery at MD Anderson. “Fannin’s Raptamer drug discovery platform represents an innovative new modality that offers the potential to enhance our portfolio of novel therapies, and we look forward to the opportunities ahead.”

Fannin and MD Anderson will design translational studies together and collaborate to select promising targets for drug discovery. This is a great deal for Fannin, which will retain commercialization rights for the assets that are developed. But MD Anderson won’t be left out; the institution is eligible to receive some payments based on the success of Radiomers and other Raptamer-based drugs developed through the collaboration.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

From Your Site Articles
Radiomer Therapeutics has launched under Fannin Partners with an undisclosed amount of seed funding. Photo via Getty Images

Early-stage cancer-fighting startup raises pre-seed, launches under Houston life science leader

ready to grow

Fannin Partners has done it again. The Houston-based life science development group behind medtech companies Procyrion and Allterum Therapeutics announced yesterday that it has launched Radiomer Therapeutics. With an undisclosed amount of pre-seed funding, Radiomer joins the $242 million-strong Fannin portfolio.

Radiomer uses Fannin’s proprietary Raptamer platform to target vectors and ligands for theranostic application. The cancer-fighting technology is a targeting agent that can address serious maladies including breast, lung, colorectal, prostate, and head and neck cancers.

And with Radiomer’s launch, Fannin is moving with its trademark aggressiveness. Lead programs expected to complete Phase 0 imaging/dosimetry trial(s) in cancer patients in the first quarter of next year. Those will be closely followed by therapeutic programs.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, says in a press release. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

Varadhachary has operated Radiomer in stealth mode since its 2023 inception. However, Raptamer has been in the company’s portfolio since 2019. The new company has been using the platform to generate data with the rights to radiopharmaceutical applications for the past year.

“Our lead programs include Radiomers targeting both well-established and first-in-class cancer targets,” adds Dr. Phil Breitfeld, Radiomer’s chief medical officer. “Our imaging/dosimetry trials are designed to provide clinical evidence of tumor targeting and biodistribution information, positioning us to rapidly initiate a therapeutic program(s) if successful.”

For over a decade, Fannin has developed and supported promising life science innovations by garnering grant funding and using its team of expert product developers to build out the technology or treatment. The life science innovation timeline is very different from a software startup's, which can get to an early prototype in less than a year.

"In biotech, to get to that minimally viable product, it can take a decade and tens of millions of dollars," Varadhachary said on the Houston Innovators Podcast earlier this year.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston Methodist receives record $110M gift, names future tower

historic gift

Houston Methodist has received the largest gift in the health system's history to establish new funds for neurological, neuroscience, and women’s health research and treatment.

The $110 million gift comes from Houston-based The Brockman Medical Research Foundation, which supports education and research in the science, medicine and healthcare fields. In response, Houston Methodist announced that it will name its forthcoming 26-story hospital facility the Brockman Centennial Tower.

The tower’s entrance will be named the Anna Margaret Bellows Centennial Hall to honor Anna Margaret Bellows, a young camper who died during the Camp Mystic flooding last summer.

“This extraordinary gift accelerates discovery and transforms how care is delivered,” Dr. Marc Boom, president and CEO of Houston Methodist, said in a news release. “We are grateful to The Brockman Medical Research Foundation for its incredible generosity and vision that will help change the lives of generations of patients. Naming Centennial Tower in recognition of this gift reflects the scale of this commitment and its impact on the future of neuroscience, neurological care and women’s health.”

The gift will be divided into two parts:

  • $100 million will go toward creating an innovation fund within the Houston Methodist Academic Institute and the Houston Methodist Neurological Institute
  • $10 million will be devoted to Houston Methodist's Department of Obstetrics and Gynecology

“This tremendous gift will accelerate translational research that broadens our understanding of neurological and other diseases,” Dr. Jenny Chang, president and CEO of the Houston Methodist Academic Institute, added in the release. “It will allow us to leverage state-of-the-art platforms to detect, diagnose and deliver therapeutics, keeping patient care at the center of our mission.”

The Brockman Centennial Tower is expected to open next year in the Texas Medical Center. Spanning more than 1 million square feet, it will house 400 patient beds, an expanded emergency department, new operating rooms and a rooftop garden. It will be connected to Houston Methodist's flagship Paula and Joseph C. “Rusty” Walter III Tower, which opened in 2018. The Centennial Tower was estimated to cost $1.4 billion when announced in 2022.

In addition to the news of the Brockman gift, Houston Methodist also announced this month that it has launched the Houston Methodist Center for Cell and Gene Therapy and tapped an internationally recognized scientist as its leader.

The new center is focused on discovering and developing innovative and cost-effective therapies for a variety of congenital and acquired diseases, including cancer, HIV and cardiovascular disease.

Dr. Malcolm Brenner has been named as the center's inaugural leader and will assume the role starting in October. He will work alongside scientists and support staff from Baylor College of Medicine and Texas Children's Hospital.

Brenner is a professor of pediatrics, medicine, molecular and human genetics and translational biology at Baylor College of Medicine. He is known for making early advances in using bone marrow transplantation as a form of cell therapy and in engineered immune-cell treatments for cancer and infections, according to a release from Houston Methodist.

“Malcolm Brenner is a pioneer in the field of cell and gene therapy and is uniquely qualified to lead Houston Methodist’s research efforts in this field,” Chang added. “His vision and leadership will play a pivotal role in advancing our work in this space.”

Report: Houston reclaims top 10 ranking among America's best cities

Houston has made a triumphant return to America's 10 best cities for 2026, certifying the city is a cornerstone of the country's growth and economic prosperity.

Houston ranks No. 9 nationwide in the annual "America's Best Cities" report from Canada-based real estate and tourism marketing firm Resonance Consultancy. Each year, the report ranks the relative qualities of livability, cultural "lovability," and economic prosperity in 393 American cities with metropolitan populations of 500,000 or more.

Dallas surpassed H-Town as the No. 8 best city in America, and the Lone Star State boasts a strong presence among the top 25. Austin and San Antonio, respectively, were named the 11th and 24th best American cities this year.

Previously, Houston was dubbed the 13th best American city in 2025, down from its No. 10 ranking in the 2024 report.

Rather than profiling each individual city like in past reports, the 2026 edition focuses on regional and state prosperity. Texas' economic dominance is second only to Florida's, and the state's growth is solidified by the Dallas-Houston-Austin "triangle," where each metro has its own distinct economic identity, but when combined "form one of the most formidable regional economies in the world."

"In our 2026 survey, Dallas ranks third nationally as the place Americans believe offers the best job opportunities, Austin fifth, and Houston seventh," the report's author wrote. "That concentration of perceived economic opportunity in a single state is unmatched, and the GDP data confirms it isn’t just perception."

After being named one of the best places to start a business or a career earlier in 2026, Houston has continued to punch above its weight with its success in tourism, education, and housing growth.

Overall, the report found a correlation between a city's population growth and its latest ranking, with bigger cities appearing higher up on the list. The top three best American cities — New York, Los Angeles, and Chicago — are coincidentally the three largest metros, while Dallas and Houston are the fourth and fifth largest but appear eighth and ninth on the list.

"Scale compounds at the large city level — more people generate more economic activity, more cultural infrastructure, more employer presence, which attracts more people," the report said.

The top 10 best cities in America for 2026 are:

  • No. 1 – New York
  • No. 2 – Los Angeles
  • No. 3 – Chicago
  • No. 4 – Miami
  • No. 5 – San Francisco
  • No. 6 – Seattle
  • No. 7 – Las Vegas
  • No. 8 – Dallas
  • No. 9 – Houston
  • No. 10 – Boston

New probe into Tesla after vehicle slams into Houston-area home at high speed

Tesla Talk

The top U.S. auto regulator opened an investigation Monday, June 22, after a Tesla using an automated driving feature slammed into a Texas home at high speed and killed a 76-year-old woman standing inside.

The National Highway Traffic Safety Administration said it's opening a special investigation into the Tesla Model 3 crash on Friday near Houston, a significant probe because the car was using technology that Elon Musk considers key to the company's future.

The Tesla CEO is rolling out robotaxis using automated software in several U.S. cities this year and plans to invite Tesla owners to put their cars into the fleet using the same system across the country.

The driver told the Harris County Sheriff's Office that he was using the technology, according to a police report on the crash, but it's not clear what role, if any, it played in the incident.

Tesla did not respond to a request for comment but the head of the company's artificial intelligence efforts suggested on social media later Monday that the self-driving feature was not to blame.

“In this case, the driver manually overrode self-driving by pressing the accelerator all the way to 100% of the accel pedal in this residential area,” wrote Ashok Elluswamy on X, the platform that is now part of Musk's rocket company, SpaceX. “They reached a speed of 73 mph during the crash, and had the accelerator pressed even after the crash.”

The police report noted that the driver was not drunk and is cooperating. It identified the woman killed as Martha Avila.

Video obtained by KHOU-TV shows the car traveling at top speed over the front lawn of a brick home in Katy, then ramming into a front room. The next shot shows the car encased in the home amid piles of crumbling plaster, split beams and bits of furniture.

The auto safety regulator, known as NHTSA, has launched several investigations into Tesla, including one late last year into 58 incidents in which Teslas reportedly violated traffic safety laws while using self-driving technology, leading to more than a dozen crashes and fires and nearly two dozen injuries.

A few months earlier, the NHTSA opened an investigation into why Tesla apparently had not been reporting crashes promptly as required.

As for special crash investigations, the NHTSA has opened 46 involving Teslas using self-driving or driver-assistance technology over the past decade, according to the agency's records. In more than a dozen of those crashes, at least one person — a driver, passenger or pedestrian — was killed.

Tesla stock fell sharply early last year as car sales plunged amid a boycott of Musk after he waded into politics, leading President Donald Trump's budget-cutting Department of Government Efficiency initiative and embracing European extremist candidates.

Musk has since shifted the Tesla story to one less about car sales and more about AI and robotaxis, and done so successfully. The stock is up 16% in the past year.

View All Listings